Mrs. Lila M Mourning, ARNP-C Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 101 E Ross St, Clearwater, KS 67026 Phone: 620-584-2055 Fax: 620-584-2032 |
News Archive
Low doses of a commonly used atypical antipsychotic drug improved survival in a mouse model of anorexia nervosa, University of Chicago researchers report this month. The result offers promise for a common and occasionally fatal eating disorder that currently lacks approved drugs for treatment.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
She knew it wasn't a good idea and her daughter would disapprove. Nonetheless, Barbara Figge Fox, 79, recently went to four stores in Princeton, New Jersey, to shop for canned goods, paper towels, fresh fruit, yogurt, and other items.
Walter and Eliza Hall Institute scientists have created a weakened strain of the malaria parasite that will be used as a live vaccine against the disease. The vaccine, developed in collaboration with researchers from the US, Japan and Canada, will be trialled in humans from early next year.
InterSystems Corporation, the global leader in software for connected healthcare, today announced that CareGroup Healthcare System, a Boston-based integrated delivery network (IDN) comprised of four hospitals, has selected the InterSystems Ensemble® rapid integration and development platform to replace its legacy eGate platform for strategic integration throughout the organization.
› Verified 9 days ago